Neurocrine Biosciences, Inc. presented new data from the open-label KINECT-HD2 study demonstrating an established long-term safety profile, tolerability and sustained improvements in chorea severity through three years of… read more.
Arcutis Biotherapeutics, Inc. announced that the FDA has approved the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream 0.05% for the topical treatment of mild to moderate… read more.
Camurus announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Oczyesa, (octreotide subcutaneous depot), marketing authorization for the maintenance treatment in adult patients with… read more.
Novavax Inc. announced a milestone payment from Takeda has been triggered by regulatory approval in Japan for Novavax’s Covid-19 vaccine Nuvaxovid 2025-2026 Formula (Intramuscular Injection 1 mL) formulated… read more.
Merck KGaA, announced that the European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing… read more.
Eisai Co., Ltd. announced that the in-house discovered and developed orexin receptor antagonist Dayvigo (brand name in China: “达卫可®“ generic name: lemborexant) has launched in China for the… read more.
NICE(UK): Guselkumab can be used as an option for previously treated moderately to severely active Crohn’s disease in adults, when: i) conventional or biological treatment: a) has not… read more.
NICE (UK): Pembrolizumab with carboplatin and paclitaxel can be used, within its marketing authorisation, as an option for untreated primary advanced or recurrent endometrial cancer in adults. It… read more.
Datroway (datopotamab deruxtecan) has been approved in China for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+… read more.
NICE (UK): Idebenone is recommended, within its marketing authorisation, as an option for treating visual impairment in Leber’s hereditary optic neuropathy (LHON) in people 12 years and over…. read more.
NICE (UK): Guselkumab can be used as an option for treating moderately to severely active ulcerative colitis in adults when: i) a conventional treatment, biological treatment or Janus… read more.
NICE (UK): Tarlatamab should not be used to treat extensive-stage small-cell lung cancer in adults whose cancer has progressed after 2 or more lines of treatment, including platinum-based… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
